Format

Send to

Choose Destination
Mamm Genome. 2016 Oct;27(9-10):460-8. doi: 10.1007/s00335-016-9655-6. Epub 2016 Jul 8.

Heritability of in vitro phenotypes exhibited by murine adipose-derived stromal cells.

Author information

1
Department of Foods and Nutrition, University of Georgia, 305 Sanford Drive, Athens, GA, 30602, USA.
2
The Jackson Laboratory, Bar Harbor, ME, 04609, USA.
3
Department of Foods and Nutrition, University of Georgia, 305 Sanford Drive, Athens, GA, 30602, USA. rpazdro@uga.edu.

Abstract

Adipose-derived stromal cells (ADSCs) exhibit significant potential as therapeutic agents to promote tissue regeneration. Success of ADSC-based therapies is dependent upon efficient cell expansion in vitro as well as postinjection survival in the caustic milieu of damaged tissue. Genetic background regulates ADSC proliferative capacity and stress resistance, but the extent of the genetic effect size is not completely defined. The present study aimed to quantify phenotypic ranges and heritability of in vitro ADSC characteristics. ADSCs were isolated from mice representing 16 genetically diverse inbred mouse strains, including 12 classical inbred strains and four wild-derived strains. Cells were grown in vitro, and proliferative capacity and oxidative stress resistance were assessed. The fold change for ADSC growth ranged from 0.87 (BALB/cByJ) to 23.60 (POHN/DehJ), relative to original seeding density. The heritability of proliferative capacity was estimated to be 0.6462 (p = 9.967 × 10(-15)), and this phenotype was not associated with other ADSC traits. Cell viability following H2O2 treatment ranged from 39.81 % (CAST/EiJ) to 91.60 % (DBA/2 J), and the heritability of this phenotype was calculated as 0.6146 (p = 1.22 × 10(-12)). Relationships between cell viability and weight of the donor fat pad were also discovered. Donor genetic background is a major determinant of in vitro ADSC phenotypes. This study supports the development of forward genetics strategies to identify genes that underlie ADSC phenotypic diversity, which will inform efforts to improve cell-based therapies.

PMID:
27393554
DOI:
10.1007/s00335-016-9655-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center